{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:16Z","timestamp":1791493636568,"version":"4.3.4"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chemical ablation was designed to inject chemical agents directly into solid tumors to kill cells and is currently only used clinically for the palliative treatment of tumors. The application and combination of different drugs, from anhydrous ethanol, and glacial acetic acid to epi-amycin, have been clinically tested for a long time. The effectiveness is unsatisfactory due to chemical agents\u2019 poor diffusion and concentration. Immunotherapy is considered a prospective oncologic therapeutic. Still, the clinical applications were limited by the low response rate of patients to immune drugs and the immune-related adverse effects caused by high doses. The advent of intratumoral immunotherapy has well addressed these issues. However, the efficacy of intratumoral immunotherapy alone is uncertain, as suggested by the results of preclinical and clinical studies. In this study, we will focus on the research of immunosuppressive tumor microenvironment with chemoablation and intratumoral immunotherapy, the synergistic effect between chemotherapeutic drugs and immunotherapy. We propose a new concept of intratumoral chemo-immunoablation. The concept opens a new perspective for tumor treatment from direct killing of tumor cells while, enhancing systemic anti-tumor immune response, and significantly reducing adverse effects of drugs.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1057535","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:30:07Z","timestamp":1673505007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Chemo-immunoablation of solid tumors: A new concept in tumor ablation"],"prefix":"10.3389","volume":"13","author":[{"given":"Liangliang","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2019.19246","article-title":"Percutaneous cryoablation in early stage hepatocellular carcinoma: Analysis of local tumor progression factors","volume":"26","author":"Kim","year":"2020","journal-title":"Diagn Interv Radiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13766","article-title":"Local thermal ablative therapies for extracranial oligometastatic disease of non-Small-Cell lung cancer","author":"Kong","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112511","article-title":"Ablation in pancreatic cancer: Past, present and future","volume":"13","author":"Narayanan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2145","article-title":"Ct-guided percutaneous chemical ablation of adrenal neoplasms","volume":"190","author":"Xiao","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1051-0443(07)61792-8","article-title":"Chemical ablation of hepatocellular carcinoma","volume":"13","author":"Clark","year":"2002","journal-title":"J Vasc Interv Radiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with bcg for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/cco.2018.04.03","article-title":"Cancer immunotherapy-the end of the beginning","volume":"7","author":"Toh","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030551","article-title":"Immune therapy resistance and immune escape of tumors","volume":"13","author":"Seliger","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"Sd-101 in combination with pembrolizumab in advanced melanoma: Results of a phase ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discovery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral immunotherapy-update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: The 'Seed and soil' hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26031","article-title":"The seed and soil hypothesis revisited\u2013the role of tumor-stroma interactions in metastasis to different organs","volume":"128","author":"Langley","year":"2011","journal-title":"Int J Cancer"},{"key":"B16","article-title":"Paget's \"Seed and soil\" hypothesis revisited","volume":"9","author":"Amerasekera","year":"2004","journal-title":"J BUON"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844142","article-title":"Immunotherapy: Reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103773","article-title":"Tumor infiltrating lymphocytes (Tils) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review","volume":"177","author":"Presti","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.156021","article-title":"Macrophages promote growth, migration and epithelial-mesenchymal transition of renal cell carcinoma by regulating Gsdmd\/Il-1beta axis","volume":"159","author":"Xie","year":"2022","journal-title":"Cytokine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: Mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.Cir-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.988295","article-title":"Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3032","article-title":"Identification of epigenetically silenced genes in tumor endothelial cells","volume":"67","author":"Hellebrekers","year":"2007","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403355","article-title":"Crosstalk between angiogenesis and lymphangiogenesis in tumor progression","volume":"18","author":"Scavelli","year":"2004","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55185","article-title":"The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy","volume":"9","author":"Lim","year":"2020","journal-title":"Elife"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the pd-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s40425-019-0724-8","article-title":"Intratumoral immunotherapy with Tlr7\/8 agonist Medi9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","volume":"7","author":"Mullins","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016151807","article-title":"Percutaneous ct-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: A propensity score-matching analysis","volume":"282","author":"Pan","year":"2017","journal-title":"Radiology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3171\/2016.8.FOCUS16319","article-title":"Introduction: Laser ablation techniques","volume":"41","author":"Barnett","year":"2016","journal-title":"Neurosurg Focus"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1967.00980030203014","article-title":"The joule Thomson cryoprobe","volume":"78","author":"Amoils","year":"1967","journal-title":"Arch Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2012.04.035","article-title":"Ct-guided conformal cryoablation for peripheral nsclc: Initial experience","volume":"81","author":"Zhang","year":"2012","journal-title":"Eur J Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081609","article-title":"Irreversible electroporation (Ire) in locally advanced pancreatic cancer: A review of current clinical outcomes, mechanism of action and opportunities for synergistic therapy","volume":"10","author":"Rai","year":"2021","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7785\/tcrt.2012.500254","article-title":"Ct-guided percutaneous chemoablation using an ethanol-Ethiodol-Doxorubicin emulsion for the treatment of metastatic lymph node carcinoma: A comparative study","volume":"12","author":"Liu","year":"2013","journal-title":"Technol Cancer Res Treat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.62.03.0001","article-title":"Intratumoural chemotherapy of lung cancer for diagnosis and treatment of draining lymph node metastasis","volume":"62","author":"Celikoglu","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1227\/00006123-199512000-00013","article-title":"Intratumoral chemotherapy","volume":"37","author":"Walter","year":"1995","journal-title":"Neurosurgery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071754","article-title":"Intratumoral immunotherapy and tumor ablation: A local approach with broad potential","volume":"14","author":"Senders","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"eabn5859","DOI":"10.1126\/sciimmunol.abn5859","article-title":"Intratumoral immunotherapy relies on b and T cell collaboration","volume":"7","author":"Sagiv-Barfi","year":"2022","journal-title":"Sci Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004799","article-title":"Intratumoral immunotherapy using a Tlr2\/3 agonist, l-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3642","article-title":"Intratumoral immunotherapy for early-stage solid tumors","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: Immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J Med Toxicol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: Developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S247050","article-title":"Toll-like receptor 9 agonists in cancer","volume":"13","author":"Karapetyan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002876","article-title":"Intratumoral injection of Tlr9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-Pd1 in pancreatic cancer","volume":"9","author":"Carbone","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-vec) in patients with melanoma treated in the optim phase iii clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia jx-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-vec), a first-in-Class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1889822","article-title":"Tim-3 levels correlate with enhanced nk cell cytotoxicity and improved clinical outcome in aml patients","volume":"10","author":"Rakova","year":"2021","journal-title":"Oncoimmunology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1984677","article-title":"Trial watch: Intratumoral immunotherapy","volume":"10","author":"Humeau","year":"2021","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/ajt.16105","article-title":"Intratumoral immunotherapy with anti-Pd-1 and Tlr9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts","volume":"21","author":"Dang","year":"2021","journal-title":"Am J Transplant"},{"key":"B58","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","article-title":"Immunotherapeutic effects of intratumoral nanoplexed poly I:C","volume":"7","author":"Aznar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002845","article-title":"Tlr3-specific double-stranded rna oligonucleotide adjuvants induce dendritic cell cross-presentation, ctl responses, and antiviral protection","volume":"186","author":"Jelinek","year":"2011","journal-title":"J Immunol"},{"key":"B60","article-title":"[Chemotherapy]","volume":"72","author":"Fujita","year":"2014","journal-title":"Nihon Rinsho"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S46393","article-title":"Intratumoral chemotherapy for lung cancer: Re-challenge current targeted therapies","volume":"7","author":"Hohenforst-Schmidt","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70245-b","article-title":"The effect of intralesional 5-fluorouracil therapeutic implant (Mpi 5003) for treatment of basal cell carcinoma","volume":"27","author":"Orenberg","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1053\/jhep.1996.v23.pm0008621181","article-title":"Prognosis of small hepatocellular carcinoma (Less than 3 Cm) after percutaneous acetic acid injection: Study of 91 cases","volume":"23","author":"Ohnishi","year":"1996","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-007-0409-3","article-title":"Apoptosis in alpha interferon (Ifn-alpha) intratumoral chemotherapy for cystic craniopharyngiomas","volume":"23","author":"Ierardi","year":"2007","journal-title":"Childs Nerv Syst"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9220","article-title":"[Ct-guided percutaneous intratumoral chemotherapy with a novel Cisplatin\/Epinephrine injectable gel for the treatment of inoperable malignant liver tumors]","volume":"172","author":"Engelmann","year":"2000","journal-title":"Rofo"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/000348940411300312","article-title":"Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors","volume":"113","author":"Duvillard","year":"2004","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-005-1208-3","article-title":"Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children","volume":"21","author":"Takahashi","year":"2005","journal-title":"Childs Nerv Syst"},{"key":"B69","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.Focus09310","article-title":"Craniopharyngiomas: Intratumoral chemotherapy with interferon-alpha: A multicenter preliminary study with 60 cases","volume":"28","author":"Cavalheiro","year":"2010","journal-title":"Neurosurg Focus"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0224-0","article-title":"Chemical ablation therapy of recurrent mediastinal nodal metastasis in post-radiotherapy cancer patients","volume":"31","author":"Xu","year":"2014","journal-title":"Med Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.02.006","article-title":"Prospective multicentered safety and feasibility pilot for endobronchial intratumoral chemotherapy","volume":"156","author":"Yarmus","year":"2019","journal-title":"Chest"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.05.024","article-title":"Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. gustave roussy's initial experience with its first 100 patients","volume":"172","author":"Tselikas","year":"2022","journal-title":"Eur J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2727-2_19","article-title":"A phase 2, open-label, randomized study of pexa-vec (Jx-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma","volume":"1317","author":"Breitbach","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (Panfire-iii). a phase-I study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10 Mg\/Kg versus ipilimumab 3 Mg\/Kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of ctla-4 blocking antibody induces Cd8+ T-Cell-Dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10453","article-title":"A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma","volume":"7","author":"Ray","year":"2016","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-018-4764-0","article-title":"'Durvit': A phase-I trial of single low-dose durvalumab (Medi4736) intratumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour- and lymph node microenvironment","volume":"18","author":"Rotman","year":"2018","journal-title":"BMC Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00271-4","article-title":"Intralesional tti-621, a novel biologic targeting the innate immune checkpoint Cd47, in patients with relapsed or refractory mycosis fungoides or s\u00e9zary syndrome: A multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03051-x","article-title":"The pivotal role of cytotoxic nk cells in mediating the therapeutic effect of anti-Cd47 therapy in mycosis fungoides","volume":"71","author":"Kruglov","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of ctla-4 and pd-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: A phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001444","article-title":"Current progress and future perspectives of neoadjuvant anti-Pd-1\/Pd-L1 therapy for colorectal cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1801527","DOI":"10.1002\/adma.201801527","article-title":"Injectable bioresponsive gel depot for enhanced immune checkpoint blockade","volume":"30","author":"Yu","year":"2018","journal-title":"Adv Mater"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20140547","article-title":"A review of performance of near-infrared fluorescence imaging devices used in clinical studies","volume":"88","author":"Zhu","year":"2015","journal-title":"Br J Radiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e000579","DOI":"10.1136\/jitc-2020-000579","article-title":"Pickering Emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-Ctla4 immune checkpoint antibodies","volume":"8","author":"Tselikas","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/934947","article-title":"Contrast media: Are there differences in nephrotoxicity among contrast media","volume":"2014","author":"Solomon","year":"2014","journal-title":"BioMed Res Int"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-006-1055-1","article-title":"[Future of chemotherapy]","volume":"45","author":"Grimm","year":"2006","journal-title":"Urologe A"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: Harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.2c12969","article-title":"Combined chemo-Immuno-Photothermal therapy for effective cancer treatment Via an all-in-One and one-for-All nanoplatform","volume":"14","author":"Yu","year":"2022","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1057535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:30:10Z","timestamp":1673505010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1057535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":90,"alternative-id":["10.3389\/fimmu.2022.1057535"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1057535","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"article-number":"1057535"}}